8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
BeiGene has launched Tevimbra (tislelizumab) in the USA for the treatment of certain adults with esophageal squamous cell carcinoma (ESCC), after chemo. 7 October 2024
Kezar Life Sciences has paused its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 7 October 2024
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
A stern letter has been written to the US Food and Drug Administration (FDA) by the chairs of two US congressional committees, demanding answers in relation to the approval of Biogen and Eisai’s Alzheimer’s drug, Aduhelm (aducanumab). 3 September 2021
Today the European Union and AstraZeneca reached an agreement which will secure the delivery of the remaining COVID-19 vaccine doses to member states under the terms of the Advance Purchase Agreement concluded on August 27, 2020 with UK pharm major AstraZeneca. 3 September 2021
Kees Melief, chief scientific officer of ISA Pharmaceuticals, provides an Expert View on why therapeutic cancer vaccines will be a success following many years of being out of favor. 3 September 2021
Shares of Swedish Orphan Biovitrum, also known as Sobi, jumped as much as 23.6% to 235 Swedish kronor early today, after the company revealed it has received a takeover bid. 3 September 2021
Ultomiris (ravulizumab) has now been approved in the European Union for expanded use to include children (with a body weight of 10 kg or above) and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). 3 September 2021
Swedish biotech pairing Alligator Bioscience and Scandion Oncology have concluded a research collaboration, describing its outcome as positive. 2 September 2021
A US Food and Drug Administration (FDA) review of a large clinical trial has led the agency to conclude that JAK inhibitors lead to an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death. 2 September 2021
Precision BioSciences and UK biotech Tiziana Life Sciences have entered an exclusive license agreement to explore Tiziana's foralumab, a fully human anti-CD3 monoclonal antibody (MAb), as an agent to induce tolerance of allogeneic CAR T-cells to potentially improve the clinical outcome of CAR-T cell therapy. 2 September 2021
Brukinsa (zanubrutinib) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 2 September 2021
Another coronavirus vaccine is moving towards the finishing line, as South Korean firm SK Bioscience announced the initiation of Phase III tests for its candidate, GBP510. 1 September 2021
GlaxoSmithKline has launched its shingles vaccine, Shingrix (zoster vaccine recombinant), in the UK. The vaccine will be available to purchase from pharmacies and private healthcare practices, as well as through a national immunization program for people in their seventies. 1 September 2021
Merck & Co has announced a label update for Keytruda (pembrolizumab), the US pharma giant’s blockbuster anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the USA. 1 September 2021
All signs point to an M&A boom in late 2021 and throughout 2022. In this episode, Lance Minor, principal and national co-leader of the life sciences practice at BDO, provides valuable insight into current and emerging trends in the biotech investing landscape. 1 September 2021
Japanese pharma major Astellas Pharma has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM). 1 September 2021
Swiss pharma giant Novartis has reached a commercial agreement with the National Health Service (NHS) in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address elevated "bad" low-density lipoprotein (LDL)-cholesterol in eligible patients with atherosclerotic cardiovascular disease (ASCVD) across England. 1 September 2021
The US Centers for Disease Control and Prevention (CDC) has officially endorsed the recommendation for use of tozinameran, the coronavirus vaccine produced by Pfizer and BioNTech. 31 August 2021
Shares in AC Immune were up on Tuesday, after the firm announced encouraging results from a Phase II trial of its Alzheimer’s disease (AD) candidate. 31 August 2021
Chinese biopharma firm Innovent Biologics and US biotech Bolt Biotherapeutics have announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates. 31 August 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.